GOVX
- GeoVax Labs, Inc.
()
Overview
Company Summary
GeoVax Labs, Inc. is a biotechnology company focused on developing innovative vaccines to combat various infectious diseases. The company specializes in advancing its novel vaccine platforms that are designed to stimulate durable immune responses against targeted viruses and bacteria.
One of GeoVax's main areas of focus is the development of vaccines against HIV (Human Immunodeficiency Virus), the virus that causes AIDS (Acquired Immunodeficiency Syndrome). The company has an extensive pipeline of HIV vaccine candidates, utilizing its MVA (Modified Vaccinia Ankara) and DNA (Deoxyribonucleic Acid) platforms. These platforms are designed to deliver specific HIV antigens to stimulate immune responses and potentially provide long-lasting protection against the virus.
In addition to HIV, GeoVax is also involved in the development of vaccines for other infectious diseases such as hemorrhagic fever viruses like Ebola and Sudan viruses, as well as Zika virus and malaria. The company leverages its expertise in vaccine design and development to create immunogenic vaccine candidates that have the potential to prevent or treat these diseases.
Furthermore, GeoVax offers its vaccine technologies and expertise to collaborative partners for the development of vaccines for conditions like cancer and viral infections. The company's partnership model allows for the co-development of vaccines using its platforms alongside other organizations' scientific capabilities and resources.
Overall, GeoVax Labs, Inc. is dedicated to advancing the science of vaccine development and utilizing its technologies to combat infectious diseases, with a primary focus on HIV/AIDS. Through its innovative approach and collaborative efforts, the company aims to make a positive impact on global public health.